vs
Side-by-side financial comparison of CIVISTA BANCSHARES, INC. (CIVB) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $47.3M, roughly 1.0× CIVISTA BANCSHARES, INC.). CIVISTA BANCSHARES, INC. runs the higher net margin — 31.7% vs -4.8%, a 36.5% gap on every dollar of revenue. Over the past eight quarters, CIVISTA BANCSHARES, INC.'s revenue compounded faster (11.3% CAGR vs -20.2%).
Civista Bancshares, Inc. is a US-based bank holding company operating primarily across the Midwest region. It provides a full suite of personal and commercial banking services including deposit accounts, mortgage, consumer and commercial lending products, as well as wealth management solutions, serving retail consumers, small and medium-sized local businesses and community client segments.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
CIVB vs IRWD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.3M | $47.7M |
| Net Profit | $15.0M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | — | 14.3% |
| Net Margin | 31.7% | -4.8% |
| Revenue YoY | — | -47.3% |
| Net Profit YoY | 47.4% | -200.9% |
| EPS (diluted) | $0.72 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $47.7M | ||
| Q3 25 | $44.2M | $122.1M | ||
| Q2 25 | $41.4M | $85.2M | ||
| Q1 25 | $40.6M | $41.1M | ||
| Q4 24 | $40.4M | $90.5M | ||
| Q3 24 | $39.3M | $91.6M | ||
| Q2 24 | $38.1M | $94.4M |
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $-2.3M | ||
| Q3 25 | $12.8M | $40.1M | ||
| Q2 25 | $11.0M | $23.6M | ||
| Q1 25 | $10.2M | $-37.4M | ||
| Q4 24 | — | $2.3M | ||
| Q3 24 | $8.4M | $3.6M | ||
| Q2 24 | $7.1M | $-860.0K |
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | 14.3% | ||
| Q3 25 | 35.4% | 61.8% | ||
| Q2 25 | 31.1% | 53.2% | ||
| Q1 25 | 29.4% | -70.7% | ||
| Q4 24 | 28.2% | 34.8% | ||
| Q3 24 | 25.2% | 28.0% | ||
| Q2 24 | 21.2% | 26.5% |
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | -4.8% | ||
| Q3 25 | 28.9% | 32.8% | ||
| Q2 25 | 26.6% | 27.7% | ||
| Q1 25 | 25.0% | -90.9% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | 21.3% | 4.0% | ||
| Q2 24 | 18.5% | -0.9% |
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $0.01 | ||
| Q3 25 | $0.68 | $0.23 | ||
| Q2 25 | $0.71 | $0.14 | ||
| Q1 25 | $0.66 | $-0.23 | ||
| Q4 24 | $0.62 | $0.03 | ||
| Q3 24 | $0.53 | $0.02 | ||
| Q2 24 | $0.45 | $-0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $553.9M | $-261.8M |
| Total Assets | $4.3B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $215.5M | ||
| Q3 25 | — | $140.4M | ||
| Q2 25 | — | $92.9M | ||
| Q1 25 | — | $108.5M | ||
| Q4 24 | — | $88.6M | ||
| Q3 24 | — | $88.2M | ||
| Q2 24 | — | $105.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M |
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $-261.8M | ||
| Q3 25 | $499.0M | $-264.2M | ||
| Q2 25 | $404.1M | $-308.2M | ||
| Q1 25 | $397.4M | $-334.1M | ||
| Q4 24 | $388.5M | $-301.3M | ||
| Q3 24 | $394.4M | $-311.3M | ||
| Q2 24 | $373.8M | $-321.7M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $396.9M | ||
| Q3 25 | $4.1B | $396.1M | ||
| Q2 25 | $4.2B | $342.9M | ||
| Q1 25 | $4.1B | $327.2M | ||
| Q4 24 | $4.1B | $350.9M | ||
| Q3 24 | $4.1B | $389.5M | ||
| Q2 24 | $4.0B | $395.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $74.6M | ||
| Q3 25 | $19.0M | $47.6M | ||
| Q2 25 | $11.1M | $-15.1M | ||
| Q1 25 | $3.6M | $20.0M | ||
| Q4 24 | $48.2M | $15.2M | ||
| Q3 24 | $12.9M | $9.9M | ||
| Q2 24 | $12.2M | $33.5M |
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | $3.5M | $19.9M | ||
| Q4 24 | $44.1M | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M |
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | 8.5% | 48.4% | ||
| Q4 24 | 109.1% | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | 0.4% | 0.1% | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | 1.19× | ||
| Q2 25 | 1.01× | -0.64× | ||
| Q1 25 | 0.36× | — | ||
| Q4 24 | — | 6.74× | ||
| Q3 24 | 1.54× | 2.71× | ||
| Q2 24 | 1.73× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
IRWD
Segment breakdown not available.
